The cash infusion eliminates near-term financing risk and provides a clear catalyst path for EDG-7500. Traders should watch for Phase 3 initiation in Q4 2026 and potential milestone payments from Servier. The GRAND CANYON pivotal cohort top-line data for sevasemten (now owned by Servier) is also expected in Q4 2026, which could trigger milestone payments to Edgewise.
Drugs in focus
EWTX drug pipeline →EDG-15400
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Unlikely before 2029-2030 at earliest — Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
- Next catalyst
- None dated
What to watchEDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $41.27entry
- T+1 · 4mo ago −3.73%α −4.09% · $39.73
- T+5 · 4mo ago −3.66%α −2.87% · $39.76
- T+20 · 3mo ago +8.02%α +4.84% · $44.58
- T+60 · 6w ago −3.03%α −7.02% · $40.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for total potential consideration of up to $2.65 billion. The transaction transforms Edgewise into a cardiovascular-focused company and is expected to fully fund EDG-7500 development through potential approval. The closing removes deal risk and provides a strong cash runway.
Key Facts
- Edgewise received $1.55 billion in upfront cash from Servier for the sevasemten program.
- Up to $1.1 billion in additional regulatory and commercial milestones, for aggregate potential consideration of up to $2.65 billion.
- Transaction closed on July 10, 2026, as previously announced on June 1, 2026.
- Company is now a cardiovascular-focused biopharma with pipeline including EDG-7500, EDG-15400, and EDG-003.
- Phase 3 trial of EDG-7500 expected to initiate in Q4 2026; Phase 2 trial of EDG-15400 in HFpEF on track.
- Upfront proceeds plus existing cash expected to fully fund EDG-7500 development through potential approval.
Financial Impact
Edgewise receives $1.55 billion upfront cash, strengthening balance sheet by approximately 32% of pre-deal market cap ($4.9B). Total potential consideration up to $2.65 billion.
Risk Factors
- Milestone payments are contingent on regulatory and commercial success of sevasemten under Servier.
- Edgewise is now dependent on earlier-stage cardiovascular pipeline (EDG-7500, EDG-15400) with no approved products.
- Clinical trial risks for EDG-7500 and EDG-15400 could delay or derail the pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082902 |
| Document: tm2620181d1_ex99-1.htm | 0001104659-26-082902 |
| Document: 0001104659-26-082902-index-headers.html | 0001104659-26-082902 |
| Document: 0001104659-26-082902-index.html | 0001104659-26-082902 |
| Document: 0001104659-26-082902.txt | 0001104659-26-082902 |
Track record
14 reports on EWTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 1/10 Entry $43.68 Now $43.68 +0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
- Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
- Jul 13, 202618w ago 8-K Bullish 7/10 Viewing Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
- Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers